申请人:Venenum Biodesign, LLC
公开号:US20210015829A1
公开(公告)日:2021-01-21
The present invention provides compounds of Formula I:
wherein
X, R
1
, R
2
, R
3
and R
4
are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the TREX1 protein and thus can be used as medicaments for treating or preventing disorders affected by the inhibition of TREX1.